Ignite Creation Date:
2025-12-24 @ 1:48 PM
Ignite Modification Date:
2026-02-03 @ 3:43 PM
Study NCT ID:
NCT01270295
Status:
COMPLETED
Last Update Posted:
2013-03-13
First Post:
2011-01-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE).
Sponsor:
University Hospital, Clermont-Ferrand
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Receptor for advanced glycation end products (RAGE) | View |
| None | Soluble RAGE (sRAGE) | View |
| None | Endogenous secretory RAGE (esRAGE) | View |
| None | High-mobility group box-1 protein (HMGB-1) | View |
| None | Extracellular newly-identified RAGE-binding protein (EN-RAGE or S100A12) | View |
| None | Advanced glycation endproducts (AGEs) | View |
| None | Pentosidine | View |
| None | N--carboxymethyllysine | View |
| None | Acute lung injury (ALI) | View |
| None | Acute respiratory distress syndrome (ARDS) | View |
| None | Alveolar epithelium | View |
| None | Mechanical ventilation | View |
| None | Intensive Care Unit (ICU) | View |